• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Anti-N-methyl-D-Aspartate Receptor Encephalitis in 7-Month Old Infant Following Influenza Vaccination

Emily

Editor, Senior Moderator
http://www.neurology.org/content/86/16_Supplement/P5.136
[h=1]Anti-N-methyl-D-Aspartate Receptor Encephalitis in 7-Month Old Infant Following Influenza Vaccination (P5.136)[/h]
  • Madigan Army Medical Center Tacoma WA United States
  • Pediatric Critical Care Madigan Army Medical Center Tacoma WA United States

[h=2]Abstract[/h] Objective: This case describes antibody-verified anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis in a previously healthy 7 month-old infant female presenting within 48 hours of receiving an influenza booster vaccination during her first influenza season. Background: A previously healthy 7 month old infant female presented with acute onset of altered mental status, decreased activity, roving eye movements, and opisthotonic posturing within 48 hours of receiving an influenza booster vaccination. She was initially diagnosed with acute demyelinating encephalomyelitis (ADEM) and treated with a short burst of corticosteroids followed by a taper. Symptoms subjectively improved during steroid therapy but did not persist, prompting further diagnostic evaluations. Anti-NMDA receptor encephalitis was confirmed by cerebrospinal fluid antibody titer 68 days after onset of symptoms. Treatment was then undertaken with serial courses of intravenous immunoglobulin (IVIG) and rituximab. The patient?s hospital course was protracted, and she required utilization of intensive care unit resources due to aspiration risk, surgical placement of nutritional and vascular access devices, and paroxysmal autonomic hyperactivity (PAH). Minimal improvement in her neurologic exam was observed at time of hospital discharge and may be due to delayed start of treatment, as well as the cumulative effect of unrecognized seizures early in her illness course. Conclusions: This case describes the youngest patient with anti-NMDA receptor encephalitis yet reported, and the first to suggest correlation with recent influenza vaccination. As higher likelihood of neurologic recovery is associated with early initiation of treatment, providers are encouraged to consider autoimmune neurologic disorders like anti-NMDA receptor encephalitis when mental status abnormalities and developmental regression persist, regardless of patient age.
Disclosure: Dr. Cartisano has nothing to disclose. Dr. Kicker has nothing to disclose.

Wednesday, April 20 2016, 8:30 am-7:00 pm
  • Copyright ? 2016 by AAN Enterprises, Inc.
 
Back
Top Bottom